218 related articles for article (PubMed ID: 36108924)
1. The Nonirritating Concentrations of Neuromuscular Blocking Agents and Related Compounds.
Gonzalez-Estrada A; Carrillo-Martin I; Morgenstern-Kaplan D; Garzon-Siatoya WT; Renew JR; Hernandez-Torres V; Volcheck GW
J Allergy Clin Immunol Pract; 2023 Feb; 11(2):466-473.e5. PubMed ID: 36108924
[TBL] [Abstract][Full Text] [Related]
2. Neuromuscular Blockade and Reversal Practice Variability in the Outpatient Setting: Insights From US Utilization Patterns.
Bash LD; Black W; Turzhitsky V; Urman RD
Anesth Analg; 2021 Dec; 133(6):1437-1450. PubMed ID: 34784330
[TBL] [Abstract][Full Text] [Related]
3. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
Abrishami A; Ho J; Wong J; Yin L; Chung F
Cochrane Database Syst Rev; 2009 Oct; (4):CD007362. PubMed ID: 19821409
[TBL] [Abstract][Full Text] [Related]
4. Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.
Herring WJ; Woo T; Assaid CA; Lupinacci RJ; Lemmens HJ; Blobner M; Khuenl-Brady KS
J Clin Anesth; 2017 Sep; 41():84-91. PubMed ID: 28802619
[TBL] [Abstract][Full Text] [Related]
5. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
Flockton EA; Mastronardi P; Hunter JM; Gomar C; Mirakhur RK; Aguilera L; Giunta FG; Meistelman C; Prins ME
Br J Anaesth; 2008 May; 100(5):622-30. PubMed ID: 18385265
[TBL] [Abstract][Full Text] [Related]
6. Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship.
Pühringer FK; Gordon M; Demeyer I; Sparr HJ; Ingimarsson J; Klarin B; van Duijnhoven W; Heeringa M
Br J Anaesth; 2010 Nov; 105(5):610-9. PubMed ID: 20876699
[TBL] [Abstract][Full Text] [Related]
7. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
Abrishami A; Ho J; Wong J; Yin L; Chung F
Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach.
Zwiers A; van den Heuvel M; Smeets J; Rutherford S
Clin Drug Investig; 2011; 31(2):101-11. PubMed ID: 21067251
[TBL] [Abstract][Full Text] [Related]
9. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
Kotake Y; Ochiai R; Suzuki T; Ogawa S; Takagi S; Ozaki M; Nakatsuka I; Takeda J
Anesth Analg; 2013 Aug; 117(2):345-51. PubMed ID: 23757472
[TBL] [Abstract][Full Text] [Related]
10. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
Duvaldestin P; Kuizenga K; Saldien V; Claudius C; Servin F; Klein J; Debaene B; Heeringa M
Anesth Analg; 2010 Jan; 110(1):74-82. PubMed ID: 19933538
[TBL] [Abstract][Full Text] [Related]
11. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment.
Chambers D; Paulden M; Paton F; Heirs M; Duffy S; Craig D; Hunter J; Wilson J; Sculpher M; Woolacott N
Health Technol Assess; 2010 Jul; 14(39):1-211. PubMed ID: 20688009
[TBL] [Abstract][Full Text] [Related]
12. Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings.
Bash LD; Turzhitsky V; Black W; Urman RD
Adv Ther; 2021 Sep; 38(9):4736-4755. PubMed ID: 34319550
[TBL] [Abstract][Full Text] [Related]
13. Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial.
Horrow JC; Li W; Blobner M; Lombard J; Speek M; DeAngelis M; Herring WJ
BMC Anesthesiol; 2021 Feb; 21(1):62. PubMed ID: 33639839
[TBL] [Abstract][Full Text] [Related]
14. Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study.
Voss T; Wang A; DeAngelis M; Speek M; Saldien V; Hammer GB; Wrishko R; Herring WJ
Paediatr Anaesth; 2022 Mar; 32(3):436-445. PubMed ID: 34878707
[TBL] [Abstract][Full Text] [Related]
15. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
Sacan O; White PF; Tufanogullari B; Klein K
Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210
[TBL] [Abstract][Full Text] [Related]
16. Optimal anesthetic regimen for ambulatory laser microlaryngeal surgery.
Huh H; Park SJ; Lim HH; Jung KY; Baek SK; Yoon SZ; Lee HW; Lim HJ; Cho JE
Laryngoscope; 2017 May; 127(5):1135-1139. PubMed ID: 27796041
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the factors contributing to residual weakness after sugammadex administration in pediatric patients under 2 years of age.
Cates AC; Freundlich RE; Clifton JC; Lorinc AN
Paediatr Anaesth; 2024 Jan; 34(1):28-34. PubMed ID: 37792601
[TBL] [Abstract][Full Text] [Related]
18. Residual neuromuscular blockade in a real life clinical setting: correlation with sugammadex or neostigmine administration.
Batistaki C; Tentes P; Deligiannidi P; Karakosta A; Florou P; Kostopanagiotou G
Minerva Anestesiol; 2016 May; 82(5):550-8. PubMed ID: 26394365
[TBL] [Abstract][Full Text] [Related]
19. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
Blobner M; Eriksson LI; Scholz J; Motsch J; Della Rocca G; Prins ME
Eur J Anaesthesiol; 2010 Oct; 27(10):874-81. PubMed ID: 20683334
[TBL] [Abstract][Full Text] [Related]
20. Role of sugammadex in the treatment of anaphylaxis due to rocuronium in children: Extrapolation from adult and animal reports.
Ghimire A; Olbrecht VA; Tobias JD
Paediatr Anaesth; 2022 Jun; 32(6):706-715. PubMed ID: 35212434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
